Reviewing Perspective Therapeutics (NYSE:CATX) and Autonomix Medical (NASDAQ:AMIX)

Autonomix Medical (NASDAQ:AMIX) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Autonomix Medical and Perspective Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	0	0	1	0	3.00
Perspective Therapeutics	0	0	9	0	3.00

Autonomix Medical presently has a consensus target price of $28.00, indicating a potential upside of 344.44%. Perspective Therapeutics has a consensus target price of $19.43, indicating a potential upside of 468.09%. Given Perspective Therapeutics’ higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than Autonomix Medical.

Profitability

This table compares Autonomix Medical and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-542.11%	-236.92%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Earnings and Valuation

This table compares Autonomix Medical and Perspective Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$15.43 million	($16.07)	-0.39
Perspective Therapeutics	$1.43 million	161.64	-$46.51 million	N/A	N/A

Autonomix Medical has higher earnings, but lower revenue than Perspective Therapeutics.

Institutional and Insider Ownership

10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 32.4% of Autonomix Medical shares are held by insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Perspective Therapeutics beats Autonomix Medical on 6 of the 9 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.